Day: January 25, 2021

Faricimab given at intervals of up to every 16 weeks demonstrated non-inferior visual acuity gains compared to aflibercept given every eight weeks, potentially reducing the frequency of injections and overall burden of treatmentNearly half of people were treated with faricimab every 16 weeks during the first year – the first time this level of durability has been achieved in a phase III study of an injectable eye medicine for neovascular age-related macular degenerationFaricimab is the first investigational bispecific antibody designed for the eye and targets two distinct pathways – via angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) – that drive a number of retinal conditionsFaricimab was generally well-tolerated in both studies, with no new or unexpected safety signals identifiedBasel, 25 January 2021 –...

January 25, 2021Fourth-quarter highlights•        Sales amounted to EUR 6.0 billion, with 7% comparable sales growth•        Comparable order intake increased 7%•        Income from continuing operations increased to EUR 608 million, compared to EUR 550 million in Q4 2019•        Adjusted EBITA margin increased to 19.0% of sales, compared to 17.9% of sales in Q4 2019•        Income from operations improved to EUR 795 million, compared to EUR 730 million in Q4 2019•        EPS from continuing operations (diluted) amounted to EUR 0.66; Adjusted EPS increased to EUR 0.94, compared to EUR 0.83 in Q4 2019•        Operating cash flow improved to EUR 1,305 million, compared to EUR 1,271 million in Q4 2019•        Free cash flow improved to EUR 1,055 million, compared to EUR 959 million in Q4 2019Frans van Houten, CEO of Royal Philips:“Against...

This successful long-running partnership continues to evolve and bring haematology testing innovations to laboratories, globallyThe new agreement aims to utilise the IT systems to lead to improved clinical decision making and customer experienceBlood disorders have a high impact, not only for patients but for society as a whole, accounting for a third of all central laboratory tests1Basel, 25 January 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that, on 14 December, 2020, it signed a Global Business Partnership Agreement* (GBP) with Sysmex. Under this new framework, the parties renewed their commitment to the long standing Distribution, Sales and Service (DSS) agreement, allowing Roche to continue to distribute Sysmex haematology products, including instruments and reagents.2 This GBP sees the introduction of an IT...

Mont-Royal, Jan. 25, 2021 (GLOBE NEWSWIRE) — Key HighlightsZG-20-13 intersected 1,273 grams per tonne (“g/t”) Ag over 5.5m, including 3,914 g/t Ag over 1.5mZG-20-36 intersected 1,587 g/t Ag over 3mZG-SF-20-01T intersected 845 g/t Ag over 11.5mT28-20-2100-5 intersected 975 g/t Ag over 16.8mT28-20-2100-19 intersected 1,317 g/t Ag over 4.8mSurface results confirm a 90m extension to the east up to hole ZG-20-36Underground results extend the mineralisation at depth to the eastExploration and definition drilling to continue in 2021Montreal, Quebec, January 25, 2021 – Aya Gold & Silver Inc. (TSX: AYA) (“Aya” or the “Corporation”) is pleased to announce additional high-grade diamond drill hole (“DDH”) results from its 2020 drill program at the Zgounder Silver Mine in the Kingdom of Morocco. The drill results confirm high-grade...

SANTA CLARITA, Calif., Jan. 24, 2021 (GLOBE NEWSWIRE) — BioSolar, Inc. (OTC: BSRC), a developer of energy technologies, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase in a private placement offering 83,333,334 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 83,333,334 shares of common stock. The combined purchase price for one share of common stock (common stock equivalent) and a warrant to purchase one share of common stock is $0.06. The warrants have an exercise price of $0.06 per share, will be immediately exercisable and will expire five and one-half years from the issue date.H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.The gross proceeds from the...

SHANGHAI, China, Jan. 25, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that U.S. Food and Drug Administration (FDA) has granted toripalimab Fast Track designation for the first-line treatment of mucosal melanoma. Meanwhile, the FDA has also approved the Investigational New Drug (IND) application for a global Phase III trial of Toripalimab in combination with Axitinib versus Pembrolizumab for the first-line treatment of patients with advanced mucosal melanoma (Combination Clinical Trial).About ToripalimabToripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing in China. More than thirty company-sponsored clinical studies covering more...